AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

April 22, 2021 Auto Bot Alzheimer Disease, Clinical Trials, reports, Treat 0

Shots:

  • The company has completed the enrollment in the P-IIB HOPE4MCI trial evaluating the efficacy of AGB101 vs PBO in 164 patients to treat amnestic mild cognitive impairment due to AD across 23 sites in the US and Canada
  • The HOPE4MCI study followed an earlier study that showed a reduction in hippocampal overactivity and improvement in episodic memory. The HOPE4MCI study will evaluate cognitive and functional efficacy as measured by CDR-SB, MMSE, FAQ
  • The HOPE4MCI trial also includes a sub-study of brain PET imaging to measures neurodegeneration. The results of the study are expected in Nov’2022

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Report

The post AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease first appeared on PharmaShots.